CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
876.62MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.14xvs all stocks
52-Week Change
-29.05%vs all stocks
Market Capitalization
876.62MUSDvs all stocks (USD)
Enterprise Value
858.11MUSDvs all stocks (USD)
Forward P/E
-6.03xvs Biotechnology peers
Price to Book (MRQ)
7.13xvs Biotechnology peers
Enterprise to EBITDA
-5.09xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-27.48%vs Biotechnology peers
Return on Equity (TTM)
-147.41%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-168.57MUSDvs all stocks (USD)
Net Income (TTM)
-241.99MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-132.55MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-29.72MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-205.71MUSDvs all stocks (USD)
Pre-tax Income
-244.17MUSDFY2025 · Dec 31, 2025Net Income
-244.17MUSDFY2025 · Dec 31, 2025EBIT
-205.71MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-148.35MUSDFY2025 · Dec 31, 2025Research & Development
161.41MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
44.30MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.85MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-244.17MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-184.87MUSDFY2025 · Dec 31, 2025Free Cash Flow
-185.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
76.06MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-244.17MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
12.75MUSDFY2025 · Dec 31, 2025Stock-based Compensation
25.46MUSDFY2025 · Dec 31, 2025Other Non-cash Items
27.63MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.54MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-938.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-87.29MUSDFY2025 · Dec 31, 2025Sale of Investments
46.56MUSDFY2025 · Dec 31, 2025Other Investing Activity
1.43MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-40.24MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
126.40MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-347.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
126.06MUSDFY2025 · Dec 31, 2025Shares Outstanding
269.82MSharesUpdated Jul 19, 2026Float Shares
177.72MSharesUpdated Jul 19, 2026Shares Short
38.70MSharesUpdated Jul 19, 2026Short Ratio
9.72daysvs all stocks
Short % of Shares Outstanding
24.76%vs all stocks
% Held by Insiders
6.51%vs all stocks
% Held by Institutions
82.83%vs all stocks
Total Cash (MRQ)
101.14MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.3630USDUpdated Jul 19, 2026Total Debt (MRQ)
82.63MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6930xvs Biotechnology peers
Current Ratio (MRQ)
1.29xvs Biotechnology peers
Book Value per Share (MRQ)
0.4420USDUpdated Jul 19, 2026Total Assets
416.89MUSDvs all stocks (USD)
Total Current Assets
148.68MUSDFY2025 · Dec 31, 2025Total Liabilities
256.01MUSDFY2025 · Dec 31, 2025Total Non-current Assets
268.21MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
177.28MUSDFY2025 · Dec 31, 2025Total Current Liabilities
78.73MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
71.87MUSDFY2025 · Dec 31, 2025Other Short-term Investments
66.51MUSDFY2025 · Dec 31, 2025Accounts Payable
1.67MUSDFY2025 · Dec 31, 2025Short-term Debt
14.94MUSDFY2025 · Dec 31, 2025Other Current Liabilities
40.20MUSDFY2025 · Dec 31, 2025Long-term Debt
63.92MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
113.36MUSDFY2025 · Dec 31, 2025Common Stock (Book)
27.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.85BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
160.88MUSDvs all stocks (USD)
52-Week Low
2.61USDUpdated Jul 19, 202652-Week High
6.55USDUpdated Jul 19, 202652-Week Change
-29.05%vs all stocks
Beta
2.14xvs all stocks
50-Day MA
3.28USDUpdated Jul 19, 2026200-Day MA
3.87USDUpdated Jul 19, 2026Avg 10-Day Volume
2.87MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.71MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.9200USDUpdated Jul 19, 2026Other Income / Expense
-42.31MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Super Micro Computer Inc
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Xinjiang Zhundong Petroleum Technology Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hefei Urban Construction Group Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated